Nektar Therapeutics — Cash Flow (NASDAQ:NKTR) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities 313.29 M412.66 M304.01 M192.61 M175.71 M 189.74 M Cash from investing activities 496.21 M202.78 M365.83 M139.56 M142.57 M 61.78 M Cash from financing activities 80.35 M36.24 M1.51 M30 K42.12 M 141.98 M Free cash flow 306.03 M397.67 M298.33 M191.74 M174.24 M 189.13 M

Haberler

Oppenheimer, Nektar Therapeutics için hedef fiyatı 140 dolara yükseltti

Oppenheimer raises Nektar Therapeutics price target to $140

Nektar Therapeutics hissesi 76,3 dolarda 52 haftalık zirve yaptı

Nektar Therapeutics stock hits 52-week high at 76.3 USD

Nektar Therapeutics 4Ç 2025 sonuçları: Nakit artışı ve Ar-Ge genişlemesi

Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet

Nektar Therapeutics stock hits 52-week high at 75.19 USD

Nektar Therapeutics 460 milyon dolarlık halka arzını tamamladı